The evolving field of biodefence: therapeutic developments and diagnostics
James C. Burnetta b, Erik A. Henchalc, Alan L. Schmaljohnc, Sina Bavaric✉
- aDevelopmental Therapeutics Program, Target Structure-Based Drug Discovery Group, National Cancer Institute-SAIC, Frederick, Maryland 21702, USA
- bDevelopmental Therapeutics Program, Target Structure-Based Drug Discovery Group, National Cancer Institute-SAIC, Frederick, 21702, Maryland, USA
- cUnited States Army Medical Research Institute of Infectious Diseases, Frederick, 21702, Maryland, USA
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The threat of bioterrorism and the potential use of biological weapons against both military and civilian populations has become a major concern for governments around the world. For example, in 2001 anthrax-tainted letters resulted in several deaths, caused widespread public panic and exerted a heavy economic toll. If such a small-scale act of bioterrorism could have such a huge impact, then the effects of a large-scale attack would be catastrophic. This review covers recent progress in developing therapeutic countermeasures against, and diagnostics for, such agents.
TL;DRRecent progress in developing therapeutic countermeasures against bioterrorism and the potential use of biological weapons against both military and civilian populations is covered. (Semantic Scholar)